🔥🐔 BizChicken 🐔🔥
Companies Similar to Inhibikase Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Athira Pharma, Inc.
ATH-1017
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, with its lead product, ATH-1017, in clinical trials for Alzheimer's and Parkinson's diseases.
Symbol: ATHA
Recent Price: $0.55
Industry: Biotechnology
CEO: Dr. Mark J. Litton M.B.A., Ph.D.
Sector: Healthcare
Employees: 65
Address: 18706 North Creek Parkway, Bothell, WA 98011
Phone: 425 620 8501
Last updated: 2024-12-31
Enliven Therapeutics, Inc.
small molecule kinase inhibitors
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule inhibitors for cancer treatment, including key products ELVN-001 and ELVN-002 under clinical trials.
About | About | Directors | About | Contact | Contact | Careers | Careers | Careers | Jobs | Careers | About | Vision/Values
Symbol: ELVN
Recent Price: $22.39
Industry: Biotechnology
CEO: Mr. Samuel S. Kintz M.B.A.
Sector: Healthcare
Employees: 52
Address: 6200 Lookout Road, Boulder, CO 80301
Phone: 720 647 8519
Leadership
- Sam Kintz, Co-founder, Chief Executive Officer, and Member of the Board of Directors
- Joe Lyssikatos, Co-founder, Chief Scientific Officer
- Anish Patel, Co-founder and Chief Operating Officer
- Helen Collins, Chief Medical Officer
- Ben Hohl, Chief Financial Officer and Head of Corporate Development
- Galya Blachman, Chief Legal Officer and Head of Business Development
- Rich A. Heyman, Chairman of the Board of Directors
- Rishi Gupta, Member of the Board of Directors
- Andy Phillips, Member of the Board of Directors
- Mika Kakefuda Derynck, Member of the Board of Directors
- Jake Bauer, Member of the Board of Directors
- Rahul Ballal, Member of the Board of Directors
- Lori Kunkel, Member of the Board of Directors
- Brian Druker, Scientific Advisor
- Kevin Koch, Scientific Advisor
Last updated: 2024-12-31
Cytokinetics, Incorporated
muscle activators and inhibitors
Cytokinetics, Incorporated is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors to treat debilitating diseases.
About | About | Our Story | About | About | Our Story | Contact | Contact | About | Careers | Culture | Careers | DEI | Careers | Careers | Careers | About | About | About | About | About | News | About | News | Events | About | About | About | About | ESG | About | Contact | About | About | Vision/Values | Vision/Values | Leadership | Vision/Values | Vision/Values | Vision/Values | Vision/Values | Vision/Values | Vision/Values | About | About | About | About | About | Careers | Culture | Careers | Careers | DEI | Careers | Culture | Careers | Careers | Careers | About
Symbol: CYTK
Recent Price: $47.15
Industry: Biotechnology
CEO: Mr. Robert I. Blum
Sector: Healthcare
Employees: 423
Address: 350 Oyster Point Boulevard, South San Francisco, CA 94080
Phone: 650 624 3000
Last updated: 2024-12-31
HOOKIPA Pharma Inc.
HB-101, HB-201, HB-202, HB-300, HB-700
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing immunotherapeutics for infectious diseases and cancers using a proprietary arenavirus platform. Key products include HB-101 for kidney transplant patients, and HB-201/202 for HPV 16-positive cancers. Preclinical developments target prostate and various cancers.
Symbol: HOOK
Recent Price: $2.02
Industry: Biotechnology
CEO: Dr. Malte Peters M.D.
Sector: Healthcare
Employees: 151
Address: 350 Fifth Avenue, New York, NY 10118
Phone: 431 890 6360
Last updated: 2024-12-31
Ikena Oncology, Inc.
IK-930
Ikena Oncology is a targeted oncology company developing medicines tailored to biomarker-defined patient groups, with a focus on unmet needs in cancer treatment.
Symbol: IKNA
Recent Price: $1.60
Industry: Biotechnology
CEO: Dr. Mark Manfredi Ph.D.
Sector: Healthcare
Employees: 18
Address: 645 Summer Street, Boston, MA 02210
Phone: 857 273 8343
Last updated: 2024-12-31
INmune Bio, Inc.
INKmune
INmune Bio, Inc. is a clinical-stage immunotherapy company focused on developing drugs to reprogram the patient's innate immune system for the treatment of hematologic malignancies, solid tumors, chronic inflammation, and Alzheimer's disease.
Symbol: INMB
Recent Price: $4.65
Industry: Biotechnology
CEO: Dr. Raymond Joseph Tesi M.D.
Sector: Healthcare
Employees: 11
Address: 225 NE Mizner Boulevard, Boca Raton, FL 33432
Phone: 858 964 3720
Last updated: 2024-12-31
Kiromic BioPharma, Inc.
ALEXIS-ISO-1, ALEXIS-PRO-1
Kiromic Bio Pharma, Inc. is an artificial intelligence-driven allogeneic cell therapy company that develops multi-indication T cell therapies, leveraging the Gamma Delta T cell to target solid tumors. Key products include ALEXIS-ISO-1 and ALEXIS-PRO-1.
Symbol: KRBP
Recent Price: $0.93
Industry: Biotechnology
CEO: Mr. Pietro Bersani CPA, J.D.
Sector: Healthcare
Employees: 35
Address: 7707 Fannin, Houston, TX 77054
Phone: 832 968 4888
Leadership
- Pietro Bersani, CPA, Director
- Leonardo Mirandola, PhD, Chief Scientific Officer/Interim COO
- Scott Dahlbeck, MD, PharmD, Chief of Staff
- Brian Hungerford, Chief Financial Officer
- Michael Nagel, Chairperson
- Michael Catlin, Independent Director
- Pam Misajon, Independent Director
Last updated: 2024-12-31
Inhibrx Biosciences, Inc.
Therapeutic Candidates (INBRX-109, INBRX-106)
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.
Symbol: INBX
Recent Price: $15.14
Industry: Biotechnology
CEO: Mr. Mark Paul Lappe
Sector: Healthcare
Employees: 166
Address: 11025 North Torrey Pines Road, La Jolla, CA 92037
Phone: 858-795-4220
Last updated: 2024-12-31
Oncternal Therapeutics, Inc.
zilovertamab, ONCT-216, ONCT-808, ONCT-534
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.
Symbol: ONCT
Recent Price: $0.53
Industry: Biotechnology
CEO: Dr. James B. Breitmeyer M.D., Ph.D.
Sector: Healthcare
Employees: 27
Address: 12230 El Camino Real, San Diego, CA 92130
Phone: 858 434 1113
Last updated: 2024-12-31
Black Diamond Therapeutics, Inc.
BDTX-189, BDTX-1535, BDTX-4933
Black Diamond Therapeutics, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for patients with genetically defined tumors. The company focuses on creating irreversible small molecule inhibitors to target specific oncogenic proteins.
Symbol: BDTX
Recent Price: $2.15
Industry: Biotechnology
CEO: Dr. Mark A. Velleca M.D., Ph.D.
Sector: Healthcare
Employees: 54
Address: One Main Street, Cambridge, MA 02142
Phone: 617 252 0848
Leadership
- Ali Behbahani, M.D., Co-Head of Healthcare, NEA
- Shannon Campbell, Executive Vice President and Chief Commercial Officer, Merus
- Kapil Dhingra, M.D., Former Head, Roche Oncology Development
- Samarth (Sam) Kulkarni, Ph.D., CEO, CRISPR Therapeutics AG
- Garry E. Menzel, Ph.D., Operating Partner, GHO Capital Partners LLP
- Prakash Raman, Ph.D., CEO of InduPro, Inc.
- Mark A. Velleca, M.D., Ph.D., CEO and Board Chair
Last updated: 2024-12-31
Inhibikase Therapeutics, Inc.
Ik T-148009
Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders. Their product pipeline includes treatments for neurological and cancer-related conditions.
About | Leadership | Directors | About | About | About | Contact | Careers | About | About | About | About
Symbol: IKT
Recent Price: $3.24
Industry: Biotechnology
CEO: Dr. Milton H. Werner Ph.D.
Sector: Healthcare
Employees: 8
Address: 3350 Riverwood Parkway SE, Atlanta, GA 30339
Phone: 678 392 3419
Leadership
- Milton H. Werner, Ph.D., President and CEO
- C. Warren Olanow MD, FRCPC, FRCP (Hon.), Medical Consultant and CEO of Clintrex Research Corporation
- Garth Lees-Rolfe, CPA, Chief Financial Officer
- Dan Williams, Controller
- Terence Kelly, Ph.D., Medicinal Chemistry Consultant
- Surendra Singh, Ph.D., Chemistry and Manufacturing Controls
- Merrill M. Kraines, Partner, McDermott, Will & Emery, Outside General Counsel
- Roberto Bellini, Managing Partner at BSQUARED Capital
- Dennis Berman, Serial Entrepreneur
- David Canner, Ph.D., Partner at Soleus Capital
- Roy Freeman, M.D., Professor of Neurology at the Harvard Medical School, Director of the Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
- Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics
- Amit Munshi, Chief Executive Officer of Orna Therapeutics
Last updated: 2024-12-31
Incyte Corporation
JAKAFI, PEMAZYRE, ICLUSIG
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.
About | Leadership | Contact | Contact | Locations | Contact | Contact | Culture | Jobs | Culture | DEI | News | Events | About | About | Careers | Jobs | Careers | Careers | DEI | Culture | Careers | Culture | DEI | Careers | Locations | Careers | About | About | About | About | About | Careers | About | About | Culture
Symbol: INCY
Recent Price: $68.42
Industry: Biotechnology
CEO: Mr. Herve Hoppenot
Sector: Healthcare
Employees: 2524
Address: 1801 Augustine Cut-Off, Wilmington, DE 19803
Phone: 302 498 6700
Leadership
- Hervé Hoppenot, Chairman and Chief Executive Officer
- Paula J. Swain, Executive Vice President, Human Resources
- Pablo J. Cagnoni, M.D., President, Head of Research and Development
- Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
- Sheila A. Denton, J.D., Executive Vice President and General Counsel
- Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
- Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
- Denise Brashear, Vice President, Head of Global Communications
- Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
- Lee Heeson, Executive Vice President, Head of Incyte International
- Michael Morrissey, Executive Vice President and Head of Global Technical Operations
- Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
- Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
- Julian C. Baker, Managing Partner
- Jean-Jacques Bienaime, Former Chief Executive Officer
- Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
- Paul J. Clancy, Former Executive Vice President and Senior Advisor
- Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
- Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
- Katherine High, M.D., Former President and Head of Research and Development
- Susanne Schaffert, Ph.D., Former President
Last updated: 2024-12-31
Intensity Therapeutics, Inc.
INT230-6
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of cancer drugs for treating solid tumors. Their lead product, INT230-6, is undergoing Phase 2 trials for various cancers and is being tested in collaborations with major pharmaceutical companies.
Symbol: INTS
Recent Price: $1.82
Industry: Biotechnology
CEO: Mr. Lewis H. Bender M.A., M.B.A., M.S.
Sector: Healthcare
Employees: 5
Address: 61 Wilton Road, Westport, CT 06880
Phone: 203 221 7381
Leadership
- Lewis H. Bender, M.S., M.A., M.B.A., Founder and CEO
- Joseph Talamo, CPA, Chief Financial Officer
- James M. Ahlers, Executive Vice President
- Brian Schwartz, MD, Executive VP, Clinical Development
- John Wesolowski, CPA, MBA, Principal Accounting Officer and Controller
- Kimberly A. Guedes, RN, MBA, Vice President of Clinical Operations
- Doranne Frano, Regulatory Affairs and Quality Control
- Daniel J. Donovan, Board Member and Chief Executive Officer
- Tom Dubin, Board Member
- Mark A. Goldberg, MD, Board Member
- Emer Leahy, Ph.D., Board Member
Last updated: 2024-12-31
Kala Pharmaceuticals, Inc.
KPI-012, EYSUVIS, INVELTYS
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases using proprietary mucus penetrating particles technology.
Contact | Careers | Jobs | Careers | Careers | Careers | Careers | Leadership | Careers | Contact | Careers | Careers | Careers | About
Symbol: KALA
Recent Price: $6.87
Industry: Drug Manufacturers - Specialty & Generic
CEO: Mr. Mark T. Iwicki
Sector: Healthcare
Employees: 43
Address: 1167 Massachusetts Avenue, Arlington, MA 02476
Phone: 781 996 5252
Last updated: 2024-12-31
Kura Oncology, Inc.
ziftomenib and tipifarnib
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company developing small molecule medicines for the treatment of cancer. It focuses on genetically defined subsets of acute leukemias and has a collaboration with Novartis for certain carcinoma treatments.
Symbol: KURA
Recent Price: $8.51
Industry: Biotechnology
CEO: Dr. Troy Edward Wilson J.D., Ph.D.
Sector: Healthcare
Employees: 142
Address: 12730 High Bluff Drive, San Diego, CA 92130
Phone: 858 500 8800
Last updated: 2024-12-31
Instil Bio, Inc.
ITIL-168, ITIL-306
Instil Bio, Inc. is a clinical-stage biopharmaceutical company that develops cell therapies for treating cancer patients, focusing on autologous tumor infiltrating lymphocyte (TIL) treatments.
Symbol: TIL
Recent Price: $18.99
Industry: Biotechnology
CEO: Mr. Bronson Crouch
Sector: Healthcare
Employees: 49
Address: 3963 Maple Avenue, Dallas, TX 75219
Phone: 972 499 3350
Last updated: 2024-12-31
Viking Therapeutics, Inc.
VK2809
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, with lead drug candidate VK2809 in Phase IIb trials for non-alcoholic steatohepatitis.
Symbol: VKTX
Recent Price: $39.77
Industry: Biotechnology
CEO: Dr. Brian Lian Ph.D.
Sector: Healthcare
Employees: 30
Address: 9920 Pacific Heights Boulevard, San Diego, CA 92121
Phone: 858 704 4660
Leadership
- Lawson Macartney, DVM, Ph.D., Chairman
- Matthew W. Foehr, Chief Executive Officer
- Kathy Rouan, Ph.D.,
- Charles A. Rowland Jr.,
- Matthew Singleton,
- Brian Lian, Ph.D.,
Last updated: 2024-12-31
Denali Therapeutics Inc.
BIIB122/DNL151
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutic candidates for neurodegenerative diseases. Its pipeline includes treatments for Parkinson's disease, hunter syndrome, ALS, multiple sclerosis, and Alzheimer's disease. It collaborates with companies such as Takeda Pharmaceutical Company and Genentech, Inc.
Symbol: DNLI
Recent Price: $20.24
Industry: Biotechnology
CEO: Dr. Ryan J. Watts Ph.D.
Sector: Healthcare
Employees: 364
Address: 161 Oyster Point Boulevard, South San Francisco, CA 94080
Phone: 650 866 8548
Last updated: 2024-12-31
Nektar Therapeutics
Bempegaldesleukin
Nektar Therapeutics is a biopharmaceutical company focused on developing medicines for unmet medical needs. Their products include Bempegaldesleukin, an IL-2 pathway agonist in clinical trials for various cancers and COVID-19, and NKTR-358, a cytokine Treg stimulant for autoimmune diseases.
About | Our Story | Leadership | Directors | About | Locations | Contact | Contact | Careers | Jobs | DEI | Careers | Careers | DEI | Careers | Careers | Jobs | Jobs | About | About
Symbol: NKTR
Recent Price: $0.94
Industry: Biotechnology
CEO: Mr. Howard W. Robin
Sector: Healthcare
Employees: 137
Address: 455 Mission Bay Boulevard South, San Francisco, CA 94158
Phone: 415 482 5300
Leadership
- Howard W. Robin, President & Chief Executive Officer
- Robert Bacci, Senior Vice President, HR and Facilities Operations
- Sandra Gardiner, Chief Financial Officer
- Jennifer Ruddock, Chief Business Officer
- Mary Tagliaferri, M.D., Chief Medical Officer
- Mark A. Wilson, Chief Legal Officer
- Jonathan Zalevsky, Ph.D., Chief Research & Development Officer
Last updated: 2024-12-31
Tango Therapeutics, Inc.
TNG908
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.
Symbol: TNGX
Recent Price: $3.10
Industry: Biotechnology
CEO: Dr. Barbara L. Weber M.D.
Sector: Healthcare
Employees: 140
Address: 100 Binney Street, Cambridge, MA 02142
Phone: 857 320 4900
Last updated: 2024-12-31